Investors of Baxter International Inc. Could Lead Securities Fraud Lawsuit by December Deadline

Investors of Baxter International Inc. Urged to Act

As the December 15, 2025 deadline approaches, investors of Baxter International Inc. (NYSE: BAX) who have suffered losses exceeding $100,000 during the specified Class Period (February 23, 2022, to July 30, 2025), have a significant opportunity on their hands. Not only can they seek compensation, but they may also have the chance to lead a lawsuit against the company for allegations of securities fraud, thanks to the efforts of reputable legal counsel.

Understanding the Context

Baxter International Inc. has recently faced scrutiny, with claims that the company misled its investors. According to legal filings, the company failed to disclose critical information regarding systemic defects associated with its Novum large volume pumps (LVPs). These issues reportedly led to severe malfunctions, including under-infusion and over-infusion of fluids, which posed significant health risks to patients. The firm Rosen Law, known for its expertise in investor rights, is reaching out to affected shareholders to highlight their rights and options moving forward.

Critical Information for Investors

If you purchased Baxter common stock during the aforementioned Class Period, you may be eligible for compensation and need not worry about any out-of-pocket costs, thanks to a contingency fee arrangement. To join this important class action lawsuit, interested parties are encouraged to visit Rosen Law Firm’s website or reach out directly to attorney Phillip Kim at 866-767-3653 for more specific information related to the class action.

Why Choose Rosen Law Firm?

When it comes to investor representation, selecting the right counsel can significantly impact the outcome of a case. Rosen Law Firm prides itself on its deep track record of success, leading numerous investor rights cases with lucrative settlements. The firm has consistently ranked among the top legal practitioners in securities class action settlements, securing hundreds of millions of dollars for investors worldwide. With both experience and a commitment to client welfare, Rosen Law Firm stands out as a trusted resource.

The Allegations Unraveled

The class action lawsuit outlines serious allegations against Baxter International Inc. regarding the mishandling of important product information:
1. Systemic Defects: The Novum LVPs were reportedly plagued with systemic defects leading to malfunctions, thereby exposing patients to health risks.
2. Inadequate Remedial Action: Baxter was reportedly made aware of several device malfunctions and distressing outcomes arising from these defects but failed to act adequately in response.
3. Misleading Information: Statements made by Baxter regarding the safety, efficacy, and customer satisfaction of their products were found to be materially misleading, contributing to the damages suffered by investors once the truth emerged officially.

These allegations, when brought to light during the legal process, illustrate the significant harm that could have been avoided if accurate information had been disclosed timely to investors.

Next Steps for Investors

Eligible Baxter shareholders should consider their options carefully as the critical deadline nears. Interested parties have the right to serve as lead plaintiff in this class action, which allows them to direct the litigation process on behalf of other class members. However, it’s essential to act before December 15, 2025, to secure this position.

Investors are also reminded that until a class is formally certified, they are not represented by counsel unless individually retained. Alternatively, they can stay updated on the case without taking direct action or joining the lead plaintiff role.

Investors can follow Rosen Law Firm for pertinent updates via LinkedIn, Twitter, and Facebook.

Conclusion

Navigating the complexities of securities law and potential fraud claims can be daunting for investors. However, those impacted by the recent controversies surrounding Baxter International have a valuable opportunity for legal recourse. With the involvement of a seasoned law firm like Rosen Law, shareholders can take significant steps towards addressing their financial losses and seeking justice in the face of adversity.